Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Envisia Therapeutics
Durham, North Carolina, United Statesenvisiatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Phase II studies for ENV515 (travoprost) showed promising results with the high dose ENV515-3 demonstrating a 28% drop in pressure and 6.7 mmHg drop in IOP, numerically equivalent to Travatan Z. The low-dose (ENV515-1) showed about a 20% drop in pressure. The company was working toward optimization for anticipated Phase III studies.
- Therapeutic areas
- OphthalmologyImmunology
- Modalities
- Small moleculesparticle-based therapeutics
- Industry
- Biotech
02
Partnerships
Liquidia Technologies
Beyond the preview
Go deeper on Envisia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Envisia Therapeutics.